Ginkgo bioworks stocks.

Cutting-edge biotech company Ginkgo Bioworks Holdings ( DNA -4.79%) was a popular stock on Tuesday. The cell engineering specialist's share price zoomed more than 7% higher today, thanks to ...8,194,680. Aug 04 05:01 PM. open in yahoo open in reuters | open in marketwatch open in google open in EDGAR. DNA - Ginkgo Bioworks Holdings Inc - Stock screener for investors and traders, financial visualizations.Nov 2, 2023 ... Wall Street is positive on Ginkgo Bioworks Holdings Inc (DNA). On average, analysts give DNA a Buy rating. The average price target is ...This week was one to forget for Ginkgo Bioworks ( DNA 5.80%) shareholders. In the Monday-to-Friday period, their investment lost slightly more than 8% of its value on the stock market, according ...

Ginkgo Bioworks delivers some encouraging results. In January, Ginkgo released preliminary numbers for the full-year 2022 that indicated strong growth. The company expects its total revenue to ...Dec 1, 2023 · Many SPACs haven't lived up to their initial hype; unfortunately, Ginkgo hasn't been an exception. When its shares first began trading on the NYSE on Sept. 17, 2021, it opened at a price of $11.15 ...

Oct 6, 2023 ... Get the latest news and market analysis for Ginkgo Bioworks Holdings, Inc. (DNA). Stay up-to-date on DNA Stock price and share price with ...Nov 29, 2023 · Nov. 17. Ginkgo Bioworks Holdings Insider Sold Shares Worth $299,400, According to a Recent SEC Filing. MT. Nov. 17. Ginkgo Bioworks Holdings Insider Sold Shares Worth $112,837, According to a Recent SEC Filing. MT. Summary. Quotes. Charts.

Principal Financial Group Inc. increased its position in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Free Report) by 38.2% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 122,835 shares of the company’s stock after acquiring an additional …See the company profile for Ginkgo Bioworks Holdings, Inc. (DNA) including business summary, industry/sector information, number of employees, business summary, corporate governance, key ...Nov 29, 2023 · Ginkgo Bioworks (NYSE:DNA) Is among the more prominent stocks in the synthetic biology space. The company is located in Boston, Massachusetts, which is a leading hub in the biotechnology industry. Two major developments, including a big acquisition, are moving DNA stock today. Ginkgo Bioworks ( DNA) has agreed to acquire Bayer’s ( BAYRY) research and development center. Furthermore ...Dec 1, 2023 · Many SPACs haven't lived up to their initial hype; unfortunately, Ginkgo hasn't been an exception. When its shares first began trading on the NYSE on Sept. 17, 2021, it opened at a price of $11.15 ...

Find the latest Ginkgo Bioworks Holdings, Inc. (DNA) stock quote, history, news and other vital information to help you with your stock trading and investing.

As a member of the SPAC class of 2021, Ginkgo Bioworks ( NYSE: DNA) stock has seen its fair share of pummeling over the last few years. From an all-time high at ~$16 to the stock's current price ...

Ginkgo Bioworks Holdings, Inc. (DNA) NYSE - Nasdaq Real Time Price. Currency in USD. Follow. 2W 10W 9M. 1.4200 +0.1300 (+10.08%) As of 03:32PM EST. Market open. 1d.On 25 July 2022, Ginkgo Bioworks agreed to acquire Zymergen for $300 million in an all-stock deal. On 27 July 2022, it was reported that Ginkgo Bioworks would acquire Bayer's Biologics Research & Development site, located in West Sacramento. Ginkgo will enter into a new multi-year platform collaboration with Bayer. Nov 22, 2023 · The Ginkgo Bioworks stock price fell by -3.50% on the last day (Wednesday, 22nd Nov 2023) from $1.43 to $1.38. During the last trading day the stock fluctuated 8.82% from a day low at $1.36 to a day high of $1.48. The price has risen in 5 of the last 10 days but is still down by -7.38% for this period. Volume has increased on the last day by ... The consensus among analysts is that Ginkgo Bioworks Holdings Inc (DNA) is a Hold stock at the moment, with a recommendation rating of 2.67. 1 analysts rate the stock as a Sell, while 0 rate it as Overweight. 4 out of 9 have rated it as a Hold, with 3 advising it as a Buy. 1 have rated the stock as Underweight.8,194,680. Aug 04 05:01 PM. open in yahoo open in reuters | open in marketwatch open in google open in EDGAR. DNA - Ginkgo Bioworks Holdings Inc - Stock screener for investors and traders, financial visualizations.In the second quarter of 2022, Ginkgo Bioworks Biosecurity business generated revenue of $100 million for the company while indicating a very healthy gross profit margin of 36%. All in all, Ginkgo ...

Ginkgo Bioworks (NYSE:DNA) operates at the frontier of synthetic biology. This biotech company efficiently crafts organisms for various applications, from protein development to enzyme creation.About Ginkgo Bioworks Stock. Ginkgo Bioworks is a biotech company that designs custom microbes. The company creates custom microbes for three main areas: cultured ingredients, strain improvement, and enzymes. For cultured ingredients, Ginkgo Bioworks creates engineered yeasts to produce ingredients via fermentation for perfumes, foods ...Ginkgo Bioworks has a fantastic reputation of committing money to R&D. As an investor, I would look past current share pricing and focus on the potential 12-month upside of the company's technology.Ginkgo Bioworks Holdings, Inc ... Buyers of the stock will need to have faith that Ginkgo can accelerate their business in the future as a PS of 12.5 for a company with operating margins of -228% ...Ginkgo Bioworks is one of those stocks. The more it falls, the more likely it is that this will be at least a five-bagger investment by 2030. To get to that level, the stock wouldn't even need to ...

Key Points. Cathie Wood bought shares of Palantir, Teladoc, and Ginkgo Bioworks on Thursday. Palantir's shares have more than doubled in 2023, but the three stocks are still 31% to 94% lower than ...Boston-based Ginkgo Bioworks (NYSE: DNA) is working to develop a platform to “program cells to make everything from food to materials to therapeutics.” Industries it serves include agriculture ...

1. Progress with improving the biofoundry's margin. Ginkgo has two core goals right now: growth and profitability. Management thinks that due to economies of scale in bioengineering and ...Gingko Bioworks (NYSE:DNA) is bringing this science to the next level by introducing the power of AI to its toolkit. Ginkgo Bioworks promises that they can design and test microorganisms cheaper ...Nov 22, 2023 · According to the issued ratings of 5 analysts in the last year, the consensus rating for Ginkgo Bioworks stock is Hold based on the current 1 sell rating, 3 hold ratings and 1 buy rating for DNA. The average twelve-month price prediction for Ginkgo Bioworks is $3.19 with a high price target of $6.00 and a low price target of $1.25. Learn more ... A high-level overview of Ginkgo Bioworks Holdings, Inc. (DNA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Nov. 17. Ginkgo Bioworks Holdings Insider Sold Shares Worth $299,400, According to a Recent SEC Filing. MT. Nov. 17. Ginkgo Bioworks Holdings Insider Sold Shares Worth $112,837, According to a Recent SEC Filing. MT. Summary. Quotes. Charts.Aug 16, 2022 · Cutting-edge biotech company Ginkgo Bioworks Holdings ( DNA -4.79%) was a popular stock on Tuesday. The cell engineering specialist's share price zoomed more than 7% higher today, thanks to ... Ginkgo Bioworks stock plunged as much as 24% on Wednesday after a short-seller report from Scorpion Capital alleged that the synthetic biology company is a "Frankenstein mash-up of the worst frauds."Shares of Ginkgo Bioworks ( DNA 5.80%) were jumping 18.2% higher as of 10:58 a.m. ET. The nice gain came after the company announced its 2021 fourth-quarter and full-year results. Ginkgo reported ...

Ginkgo Bioworks Holdings Inc stock has a Growth Score of 24, Estimate Revisions Score of 29 and Quality Score of 13. Comparing United Therapeutics Corporation and Ginkgo Bioworks Holdings Inc’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your ...

Ginkgo Bioworks Reports Fourth Quarter and Full Year 2022 Financial Results. $478 million of total revenue in 2022, representing an increase of 52% over 2021 and toward the high end of guidance ...

Dec 1, 2023 · Earnings for Ginkgo Bioworks are expected to grow in the coming year, from ($0.37) to ($0.30) per share. Ginkgo Bioworks has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 6th, 2024 based off prior year's report dates. Read More. Ginkgo Bioworks Holdings, Inc. (DNA) delivered earnings and revenue surprises of 86.67% and 16.44%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead ...There was plenty of action in Ginkgo Bioworks ( DNA -2.06%) stock on Thursday, but not the kind the company probably like. Investors sold out of the biotech following the publication of its latest ...Dec 1, 2023 · Ginkgo Bioworks went public two years ago via a special purpose acquisition company. Deep losses and significant cash burn have made investors wary of investing in this risky stock. Special ... By Chris MacDonald, InvestorPlace Contributor Nov 18, 2022, 1:55 pm EST. Ginkgo Bioworks ( DNA) stock has fallen out of favor in the market. However, Cathie Wood appears to remain very bullish on ...Ginkgo Bioworks. Cathie Wood's Ark Invest is quickly building a position in a SPAC that plans to merge with Ginkgo Bioworks. The Ark Disruptive Innovation and Genomic Revolution ETFs doubled its ...By William White, InvestorPlace Writer Jul 19, 2023. Ginkgo Bioworks (DNA) stock is rising higher on Wednesday after the company won a four-year, $18 million contract from DARPA.Dec 1, 2023 · 2. Ginkgo Bioworks. Ginkgo Bioworks has scaled up the process of engineering organisms that can be used in a variety of industries, from agriculture to pharmaceuticals. Through the company's ... This week was one to forget for Ginkgo Bioworks ( DNA 5.80%) shareholders. In the Monday-to-Friday period, their investment lost slightly more than 8% of its value on the stock market, according ...

The latest Ginkgo Bioworks Holdings stock prices, stock quotes, news, and DNA history to help you invest and trade smarter.Ginkgo Bioworks reported mixed results for Q1, sending shares lower in the after-hours session. Read why I am neutral on DNA stock.Ginkgo Bioworks ( DNA 5.80%) is having a strong showing today. Specifically, the synthetic biology company's shares were up by 10.1% on heavy volume as of 9:57 a.m. ET Wednesday morning. What's ...Ginkgo Bioworks reported Q2 revenue of $81 million, down 44% YoY, mainly due to a decline in Biosecurity revenue. Read more about DNA stock here.Instagram:https://instagram. nasdaq amgnused xbox 360 pricevhyyyy 500.com Jan 13, 2023 ... Ginkgo is down over 85% from its peak, to $1.84 per share. Its $23 billion valuation has shrunk to $2.81 billion, quickly ending Kelly's brief ... annheuser busch stock5year treasury Ginkgo Bioworks Holdings Inc stock has a Growth Score of 24, Estimate Revisions Score of 29 and Quality Score of 13. Comparing Ideaya Biosciences Inc and …Complete Ginkgo Bioworks Holdings Inc. stock information by Barron's. View real-time DNA stock price and news, along with industry-best analysis. tax rate independent contractor Complete Ginkgo Bioworks Holdings Inc. stock information by Barron's. View real-time DNA stock price and news, along with industry-best analysis.Find the latest Ginkgo Bioworks Holdings, Inc. (DNA) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.